
    
      This is a phase I, randomized, double-blind, two-group parallel, positive-controlled clinical
      trial at four centers.

      The primary objective is to assess the initial clinical safety of intravitreal injection of
      QL1205 or Lucentis® in patients with wet age-related macular degeneration (wet-AMD).

      The secondary objective are to assess the initial clinical effectiveness and pharmacokinetic
      characteristics of intravitreal injection of QL1205 or Lucentis® in patients with wet
      age-related macular degeneration (wet-AMD).

      Subjects would sequentially enrolled according to the protocol in one of two cohorts.Subjects
      would receive a single 0.5mg of QL1205 or Lucentis® once a month for three months through
      vitreous injection.
    
  